Business
Press Release Sep 15 2023
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 15, 2023, titled "Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day".
About this update from Zydus Lifesciences Limited
[{"type":"text","content":" Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 15, 2023, titled \"Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day\". View Attachment","length":397,"tagName":"div"}]